Analysts Anticipate Mesoblast limited (NASDAQ:MESO) Will Announce Quarterly Sales of $13.43 Million

Wall Street brokerages forecast that Mesoblast limited (NASDAQ:MESO) will report $13.43 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Mesoblast’s earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $24.87 million. Mesoblast reported sales of $1.97 million in the same quarter last year, which indicates a positive year-over-year growth rate of 581.7%. The business is expected to issue its next earnings report on Thursday, September 3rd.

According to Zacks, analysts expect that Mesoblast will report full year sales of $39.87 million for the current fiscal year, with estimates ranging from $19.90 million to $61.24 million. For the next year, analysts forecast that the firm will post sales of $201.50 million, with estimates ranging from $37.00 million to $518.99 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Mesoblast.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Wednesday, May 27th. The company reported ($0.14) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). Mesoblast had a negative net margin of 197.65% and a negative return on equity of 13.59%. The firm had revenue of $12.20 million for the quarter, compared to the consensus estimate of $9.38 million.

MESO has been the topic of several research reports. TheStreet upgraded shares of Mesoblast from a “d+” rating to a “c-” rating in a research note on Friday, May 22nd. Zacks Investment Research cut shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating and issued a $21.00 target price (up previously from $14.00) on shares of Mesoblast in a report on Thursday, May 28th. LADENBURG THALM/SH SH increased their target price on shares of Mesoblast from $13.00 to $15.25 and gave the stock a “buy” rating in a report on Thursday, May 28th. Finally, ValuEngine raised shares of Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Mesoblast presently has an average rating of “Buy” and an average target price of $14.91.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cetera Advisor Networks LLC acquired a new stake in Mesoblast in the 1st quarter valued at $44,000. Ingalls & Snyder LLC acquired a new stake in Mesoblast in the 1st quarter valued at $53,000. Aperio Group LLC acquired a new stake in Mesoblast in the 1st quarter valued at $81,000. Wilbanks Smith & Thomas Asset Management LLC grew its position in Mesoblast by 6.0% in the 4th quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 25,025 shares of the company’s stock valued at $184,000 after purchasing an additional 1,425 shares during the period. Finally, Morgan Stanley grew its position in Mesoblast by 93.4% in the 1st quarter. Morgan Stanley now owns 74,069 shares of the company’s stock valued at $324,000 after purchasing an additional 35,777 shares during the period. 2.12% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:MESO traded down $0.35 on Monday, hitting $11.21. The company had a trading volume of 261,337 shares, compared to its average volume of 699,581. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average price of $12.55 and a 200 day moving average price of $8.89. Mesoblast has a 1-year low of $3.12 and a 1-year high of $20.57. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -17.13 and a beta of 3.53.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Read More: Futures Contract

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.